Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITY OF EASTERN FINLAND currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio indicates that the current prosecution strategy for the university rests with the assigned individual. This interaction with 1 distinct examiner means that the requirements of the assigned official will impact the university's overall patent success. Practitioners should focus on the technical standards prevalent in the Biotechnology & Pharmaceuticals sector to ensure the claims meet the necessary requirements for allowance.
SCHMITT, MICHAEL J is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Monitoring the specific tendencies and past rulings of this examiner is necessary since there are no other active matters to provide a context for the university's standing at the office. Success in this technology area will require a response to the specific concerns raised in this pending action. Legal teams should prioritize understanding the standards of the 1 distinct art unit to effectively address this matter and ensure the application moves toward allowance. Because the busiest examiner is managing 1 pending action, the workload is limited to this matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16099035 | NANO-SYSTEMS FOR THERAPY AND/OR DIAGNOSIS AND/OR THERAPY MONITORING AND/OR THERANOSTICS OF DISEASE | SCHMITT, MICHAEL J | 44d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16099035 | NANO-SYSTEMS FOR THERAPY AND/OR DIAGNOSIS AND/OR THERAPY MONITORING AND/OR THERANOSTICS OF DISEASE | SCHMITT, MICHAEL J | 44d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16099035 | NANO-SYSTEMS FOR THERAPY AND/OR DIAGNOSIS AND/OR THERAPY MONITORING AND/OR THERANOSTICS OF DISEASE | SCHMITT, MICHAEL J | 1629 | §102§112 | Final Rejection | 44d overdue | Pending | Nov 05, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY OF EASTERN FINLAND has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael J Schmitt has the most, with 1 of UNIVERSITY OF EASTERN FINLAND's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
